Corline’s first Regenerative Medicine patent for Japan
Swedish company Corline Systems AB, maker and distributor of a proprietary and unique heparin coating technology for use in Regenerative Medicine, has been granted approval of patent application no. 2008-520221 by the Japanese Intellectual Property Office.
“This recent patent secures Corline’s core IP in yet another important world market for Regenerative Medicine, complementing the patents already granted for the world’s currently largest and most influential markets for Regenerative Medicine, i.e. US & Canada, Europe, and Australia. By merit of its broad applicability, the newly granted patents will form a cornerstone in how Corline may build its capabilities and competitive advantage in this fast evolving industry. All to the benefit of patients around the world”, comments CEO Henrik Nittmar.
The new patent – titled ‘Heparin Coating of Biological Tissue’ – covers methods for application and use of the company’s proprietary heparin coating technology for coating all types of biological tissue, such as living cells for transplantation, tissue segments and decellularized tissue matrices.
Corline is developing its technology for use in a multitude of clinical applications in the Regenerative Medicine space, both in partnership with industrial companies from many corners of the world, and together with international research groups in Europe, the US and Australia. A common denominator is that all projects use the same core technology, the one that now has gained improved protection by the newly granted patent application.
One example of Corline’s internally developed project is to use the unique heparin coating technology, CHS, to protect cells for different types of cell therapies. In this setting CHS can attenuate blood mediated inflammatory reactions and save the implanted cells from destruction when transplanted to patients. The Swedish Medical Products Agency has given its approval to start clinical trials for this promising technology for patients with severe diabetes type-1.
“On the basis of the previously communicated EU grants, we are moving into clinical trials with our core technology in Europe for cell therapy and tissue engineered vascular grafts. In parallel we are marketing our technology to several partners in the US, and the newly granted patent for Japan is important for our partners with ambitions reaching beyond their immediate domestic market”, concludes CEO Henrik Nittmar.